



0688T  
11  
10.4

R

# JOURNAL OF MOLECULAR AND APPLIED GENETICS



RECEIVED  
10-10-82  
10:15 AM

VOLUME 1 • NUMBER 4 • 1982 • RAVEN PRESS

**DOCKET**  
**ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

# Journal of Molecular and Applied Genetics

Editor-in-Chief:

Howard M. Goodman, Ph.D.

Department of Molecular Biology  
Massachusetts General Hospital  
Boston, Massachusetts 02114, U.S.A.

RECEIVED

JUL 14 1982

## Editorial Board

John Abelson, *La Jolla*  
Frederick Ausubel, *Cambridge*  
John R. Bedbrook, *Canberra*  
Lawrence Bogorad, *Cambridge*  
Mary-Dell Chilton, *St. Louis*  
Richard A. Flavell, *London*  
Raymond F. Gesteland, *Salt Lake City*  
Gary Gussin, *Iowa City*  
Dean H. Hamer, *Bethesda*  
Masayori Inouye, *Stony Brook*  
Robert Kamen, *London*  
Yuet Wai Kan, *San Francisco*  
Laurence H. Kedes, *Palo Alto*  
Daniel Klessig, *Salt Lake City*  
Thomas Maniatis, *Cambridge*  
David W. Martin, Jr., *San Francisco*  
Marc Van Montagu, *Gent*  
Richard C. Mulligan, *Cambridge*  
Alexander Rich, *Cambridge*  
Jeff Schell, *Cologne*  
James Shepard, *Manhattan*  
John Shine, *Canberra*  
Joan A. Steitz, *New Haven*  
Robert T. Tjian, *Berkeley*  
Michael Wigler, *Cold Spring Harbor*  
Patricia Zambryski, *San Francisco*

## Editorial Associates

Barbara Cordell, *Boston*  
David D. Moore, *Boston*

## Publisher

Alan M. Edelson, Ph.D., *Raven Press,  
New York*

## Publication and Advertising Staff

David A. Christie, *Production Manager,  
Raven Press, New York*  
Nancy Gordon, *Assistant to the  
Editor-in-Chief, Boston*  
Irene Rubinson, *Advertising Manager,  
Raven Press, New York*

Volume 1, Number 4, 1982

Biomedical Library UCSD

## CONTENTS

- 263 Genetic Evidence for Separate Functional Domains on the Human Adenovirus Specified, 72kd, DNA Binding Protein  
Daniel F. Klessig and Margaret P. Quinlan
- 273 Regulation *In Vivo* of a Cloned Mammalian Gene: Cadmium Induces the Transcription of a Mouse Metallothionein Gene in SV40 Vectors  
Dean H. Hamer and MaryJane Walling
- 289 Use of a *lac* Promoter-Operator Fragment as a Transcriptional Control Switch for Expression of the Constitutive *lpp* Gene in *Escherichia coli*  
Kenzo Nakamura, Yoshihiro Masui, and Masayori Inouye
- 301 An Analysis of mRNAs for a Group of Heat Shock Proteins of Soybean Using Cloned cDNAs  
Fritz Schöffl and Joe L. Key
- 315 Molecular Cloning of *Rhizobium trifolii* Genes Involved in Symbiotic Nitrogen Fixation  
K. F. Scott, J. E. Hughes, P. M. Gresshoff, J. E. Beringer, B. G. Rolfe, and J. Shine
- 327 Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter  
P. J. Southern and P. Berg

(Continued on next page)

This journal is listed in *Current Contents*.

*Journal of Molecular and Applied Genetics* (ISSN 0271-6801) published bimonthly by Raven Press, Publishers, 1140 Avenue of the Americas, New York, N.Y. 10036. Subscription rates for Vol. 1, 1981/2: Personal subscriptions \$80 in U.S., \$90 elsewhere; institutional subscriptions \$135 in U.S., \$145 elsewhere. Air delivery included for European and Mediterranean countries; for air delivery elsewhere, add \$15. Payment should accompany all orders. Please enclose present mailing label with all change of address requests. Address advertising inquiries to Advertising Manager, Raven Press. Copyright © 1982 by Raven Press.

# Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter

P. J. Southern and P. Berg

*Department of Biochemistry, Stanford University Medical Center, Stanford, California, U.S.A.*

---

**Summary:** A bacterial gene (neo) conferring resistance to neomycin-kanamycin antibiotics has been inserted into SV40 hybrid plasmid vectors and introduced into cultured mammalian cells by DNA transfection. Whereas normal cells are killed by the antibiotic G418, those that acquire and express neo continue to grow in the presence of G418. In the course of the selection, neo DNA becomes associated with high molecular weight cellular DNA and is retained even when cells are grown in the absence of G418 for extended periods. Since neo provides a marker for dominant selections, cell transformation to G418 resistance is an efficient means for cotransformation of nonselected genes.  
**Key Words:** Antibiotic resistance—Cell transformation—DNA transfection—Recombinant DNA—Bacterial genes.

---

There are two principal approaches available for the introduction of exogenous DNA into mammalian cells. Simian virus 40 (SV40) can be used as a transducing vector because it can replicate vegetatively in primate cells (1) or become integrated into host chromosomal DNA in a wide variety of cells (2). The experimental strategy has been to replace various regions of the viral genome with cloned segments of DNA and to propagate the recombinants with the aid of helper viruses in cultured animal cells (3-10). Alternatively, exogenous DNA may be introduced directly into recipient cells by either the calcium phosphate precipitation technique

(11), DEAE-dextran (12), or microinjection (13,14). The pioneering experiments for this approach relied on the transformation of TK<sup>-</sup> mammalian cell lines to a TK<sup>+</sup> phenotype with the herpes simplex thymidine kinase gene (15-17). Subsequently, unrelated DNA sequences have been integrated with the thymidine kinase gene in either linked or cotransformation experiments (18,19). Transformation of appropriate mutant cell lines has also been demonstrated with cellular DNA sequences and this approach has allowed the isolation of the chicken thymidine kinase gene (20) and the hamster adenine phosphoribosyl transferase gene (21). Morphologic transformation of normal cells forms the basis of current attempts to isolate cellular oncogenes (22,23).

Unfortunately, experiments that rely upon complementation of cell mutations by trans-

---

Received January 4, 1982; accepted February 18, 1982.  
Address correspondence and reprint requests to Dr. P. J. Southern, Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, CA 92037.

duced genes are limited by the availability of mutant mammalian cell types to serve as gene recipients. Dominant-acting genetic markers, for example, those that produce a selectable change in the phenotype of normal cells, offer a solution to this difficulty. The isolation of methotrexate-resistant transformants after transfection of normal cells with DNA from drug-resistant cells (24) exemplifies this approach. However, transformation for methotrexate-resistant dihydrofolate reductase is infrequent and, therefore, the utility for cotransformation with other genes appears limited.

Recently, our laboratory devised a family of SV40 hybrid plasmid vectors to facilitate studies of gene transfer and gene expression in mammalian cells (8,25). Plasmids containing DNA segments coding for rabbit  $\beta$ -globin (25), mouse dihydrofolate reductase (10), and *E. coli* xanthine-guanine phosphoribosyl transferase (8) can induce the synthesis of the corresponding gene products in mammalian cells. The expression of the bacterial gene, *gpt*, permits the utilization of xanthine as a substrate for the purine salvage pathway and a selection can be established in which *gpt* functions as a dominant marker for cell transformation (26). In this paper, we describe a second bacterial gene which, when incorporated into the same family of plasmid vectors, also provides a dominant selective marker for transformation of cultured mammalian cells.

The selection for transformation of mammalian cells relies on cell killing by an aminoglycoside antibiotic, G418 (27). The structure of G418 resembles gentamicin, neomycin, and kanamycin (28) but, unlike these related compounds, G418 interferes with the function of 80S ribosomes and blocks protein synthesis in eukaryotic cells (27). These aminoglycoside antibiotics can be inactivated by the bacterial phosphotransferases, APH(3')II and APH(3')I encoded by transposons Tn5 and Tn601, respectively (29). Jiminez and Davies (30) showed that yeast could be genetically transformed to G418 resistance by the phosphotransferase gene contained in Tn601 DNA. Thus, it seemed feasible (suggested by Sydney

Brenner) that the acquisition and expression of the phosphotransferase gene by mammalian cells might confer resistance to G418 toxicity. Accordingly, the phosphotransferase gene from Tn5 (designated here *neo*) (29,31) was introduced into the mammalian transcription unit of the pSV plasmid vectors. In this arrangement the SV40 early promoter is 5'-proximal, and an intron and polyadenylation signal are 3'-proximal, to the *neo* gene (8,25). Transfection of a wide variety of mammalian cell lines with these pSV-*neo* recombinants yields stable transformants that are resistant to G418 at a frequency of one transformant per  $10^4$ - $10^5$  transfected cells. Our data suggest that transformation results from the acquisition, maintenance, and continued expression of the *neo* gene in the cellular genome. Concurrent with our experiments, Colbère-Garapin et al. (32) achieved mammalian cell transformation to G418 resistance with recombinant DNA containing the Tn5 *neo* gene linked to the herpes thymidine kinase promoter DNA segment.

## MATERIALS AND METHODS

### Cells

A wide range of cultured mammalian cells are sensitive to the antibiotic G418 (Table I) and several of these have been used for transformation experiments. The cells were routinely maintained in Dulbecco-modified Eagle medium containing 10% newborn calf serum, penicillin and streptomycin, and the indicated concentrations of G418 were added to the medium.

### Enzymes

Restriction enzymes were purchased from New England Biolabs and Bethesda Research Laboratories and digestions were performed according to the supplier's specifications. T4 polynucleotide kinase was purchased from New England Nuclear and S1 nuclease from Boehringer Mannheim. T4 DNA ligase and *E. coli* DNA polymerase I were kindly provided by S. Scherer, Stanford University.

### Antibiotic G418

Samples of antibiotic G418 were generously provided by Dr. P. J. L. Daniels of Schering Corporation. Stock solutions containing 4 mg/ml G418 in 100 mM *N*-2-hydroxyethylpiperazine-*N'*-2'-ethanesulphonic acid buffer, pH 7.3, were stored at  $-20^{\circ}\text{C}$  and added in appropriate amounts to the cell culture medium. The G418 concentration refers to the actual amount of drug in the solution and takes into account that the solid material was only 40–50% G418.

### DNA Transfection and Selection of Transformed Cells

Supercoiled plasmid DNA, without added carrier DNA, was introduced into tissue culture cells ( $10\ \mu\text{g}$  for approximately  $5 \times 10^6$  cells) using the calcium phosphate precipitation technique (11) with the addition of a glycerol shock after 4 h (33). About 48 h after exposure to DNA, the cells were trypsinized and replated at a 1:20 dilution. Within 12–16 h, G418 was added to the medium at a concentration of  $100\ \mu\text{g}/\text{ml}$ . The medium plus drug was changed every 4 to 5 days. Colonies were first detected after about 7 days in the selective medium and, 1–13 days later, independent colonies were trypsinized in cloning cylinders and transferred to microtiter wells. When the colonies were small, the transplanted cells were grown non-selectively for an initial 2–3 days. Once established, the clones were expanded to stable cell lines in medium containing  $400\ \mu\text{g}/\text{ml}$  G418. In some instances, the initial selection and subcloning used  $400\ \mu\text{g}/\text{ml}$  of G418 but the transformed cells were subsequently maintained in  $100\ \mu\text{g}/\text{ml}$  of G418.

The selection strategy of permitting cell growth prior to the addition of G418 was adopted because a significant reduction in the transformation frequency occurred if G418 was added before 48 h. The transfected cells were replated at lower cell density because G418 is most effective against dividing cells. Consequently, if cells become stably transformed

early after transfection, cell division prior to selection may result in overestimation of the transformation frequency. Nevertheless, none of the transformants from randomly selected colonies appeared to have the same organization of the integrated pSV-neo DNA.

### Analysis of Transformed Cell DNAs for pSV-neo Sequences

High molecular weight cellular DNA was extracted as described by Wigler et al. (17), incubated with an excess of restriction enzyme, and the digests were separated by electrophoresis in 0.8% agarose gels. After a mild depurination reaction (34), the DNA was transferred from the gel to diazobenzoyloxymethyl paper (DBM paper) (35), hybridized with radioactively labeled DNA probes (36), and radioautographed using Kodak XR5 film and Cronex lightning fast intensification screens at  $-70^{\circ}\text{C}$  (37).

### Analysis of Cytoplasmic RNA Extracted from pSV2-neo Transformed Cells

Cytoplasmic RNA was extracted from semiconfluent cultures of transformed cells as described previously (38). The RNA was separated from contaminating DNA by pelleting through cesium chloride and then the poly A<sup>+</sup> RNA fractions were characterized using the Weaver-Weissmann variation (39) of the Berk-Sharp procedure (40). DNA hybridization probes (shown with individual experiments) were prepared by labeling appropriate restriction fragments at their 5'-ends with [ $\gamma$ -<sup>32</sup>P]-adenosine triphosphate and polynucleotide kinase (41). The DNA probes were hybridized with RNA samples under conditions of DNA excess, RNA-DNA hybrids were digested with S1 nuclease, and the protected fragments were analyzed by gel electrophoresis (39,40).

### Protein Labeling and Immunoprecipitation Reactions

Semiconfluent plates of pSV2-neo transformed cell lines were labeled for 14 h at  $37^{\circ}\text{C}$

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.